SLC5A2 and type 2 diabetes mellitus: Although these findings require validation in prospective cohorts, if they are replicated in additional studies, they support the notion that SGLT2 inhibitors act as disease-modifying drugs, with the potential to reduce the harmful long-term effects associated with an inadequate glycemic control in the early years following T2D diagnosis [250].